Gencurix Inc. (KOSDAQ: 229000)

Market Cap	29.18B
Revenue (ttm)	2.91B
Net Income (ttm)	-14.25B
Shares Out	15.24M
EPS (ttm)	-1,027.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	71,226
Open	1,990.00
Previous Close	1,989.00
Day's Range	1,869.00 - 1,998.00
52-Week Range	1,869.00 - 7,210.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Gencurix

Gencurix Inc. provide diagnostic solutions in South Korea. Its products include GenesWell BCT, a prognosis diagnostic test for breast cancer; GenesWell ddEGFR Mutation Test, a companion test for lung cancer; Droplex, a genetic test that detects DNA mutations; eDX, an early diagnosis for cancer with liquid biopsy; GenePro COVID-19 detection test; GenePro SARS-CoV-2 Test kit; GenoCTC (circulating tumor cell isolator); GenePro LAMP test solution for rapid, convenient and simple detection of various infectious diseases; and GenePro LAMP Cycler, a d...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2011
• Employees: 69
• Stock Exchange: KOSDAQ
• Ticker Symbol: 229000

Financial Performance

In 2023, Gencurix's revenue was 2.60 billion, an increase of 1.60% compared to the previous year's 2.56 billion. Losses were -19.26 billion, -21.70% less than in 2022.